AU594851B2 - Pharmaceutical compositions and their use - Google Patents

Pharmaceutical compositions and their use Download PDF

Info

Publication number
AU594851B2
AU594851B2 AU83165/87A AU8316587A AU594851B2 AU 594851 B2 AU594851 B2 AU 594851B2 AU 83165/87 A AU83165/87 A AU 83165/87A AU 8316587 A AU8316587 A AU 8316587A AU 594851 B2 AU594851 B2 AU 594851B2
Authority
AU
Australia
Prior art keywords
combination
sulfite
vanadyl
compound
vanadium compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU83165/87A
Other languages
English (en)
Other versions
AU8316587A (en
Inventor
Ephraim Kaplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU8316587A publication Critical patent/AU8316587A/en
Application granted granted Critical
Publication of AU594851B2 publication Critical patent/AU594851B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU83165/87A 1987-01-05 1987-12-31 Pharmaceutical compositions and their use Ceased AU594851B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL81166A IL81166A (en) 1987-01-05 1987-01-05 Pharmaceutically active combination comprising an ionic vanadium compound and thiosulfate or sulfite compound and optionally selenium
IL81166 1987-01-05

Publications (2)

Publication Number Publication Date
AU8316587A AU8316587A (en) 1988-07-07
AU594851B2 true AU594851B2 (en) 1990-03-15

Family

ID=11057417

Family Applications (1)

Application Number Title Priority Date Filing Date
AU83165/87A Ceased AU594851B2 (en) 1987-01-05 1987-12-31 Pharmaceutical compositions and their use

Country Status (6)

Country Link
US (1) US5045316A (OSRAM)
EP (1) EP0274404A1 (OSRAM)
JP (1) JPS63239227A (OSRAM)
AU (1) AU594851B2 (OSRAM)
IL (1) IL81166A (OSRAM)
ZA (1) ZA8841B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012563A1 (en) * 1989-04-24 1990-11-01 Board Of Regents, The University Of Texas System Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
DE4336642C2 (de) * 1993-10-22 1995-08-10 Deutsches Rheuma Forschungszen Verwendung von Vanadiumverbindungen mit antiviraler Wirkung
US5639482A (en) * 1993-11-10 1997-06-17 Crary; Ely J. Composition for control and prevention of diabetic retinopathy
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
US5871779A (en) * 1994-01-18 1999-02-16 Mount Sinai Hospital Corporation Treatment of arthropathies with vanadate compounds or analogues thereof
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US6852760B1 (en) 1998-09-17 2005-02-08 Akesis Pharmaceuticals, Inc. Compositions and methods for treatment for glucose metabolism disorders
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
AU2736400A (en) * 1999-01-27 2000-08-18 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
US20040052762A1 (en) * 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof
DE10135494A1 (de) * 2001-07-20 2003-11-06 Jobst Krauskopf Verwendung eines Lactatsalzes zur Behandlung und Prophylaxe der Athereosklerose
US7638122B2 (en) * 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
DE102004025988A1 (de) * 2004-05-21 2005-12-08 Petersen, Jan, Dr. Verwendung von Vanadylverbindungen zur Behandlung von Tumorerkrankungen
MX2015009403A (es) 2013-01-28 2017-07-04 Nuevas Alternativas Naturales Thermafat S A P I De C V Composiciones para tratamiento sistemico de condiciones patologicas resultantes de estres oxidativo y/o desequilibrio redox.
US11289700B2 (en) 2016-06-28 2022-03-29 The Research Foundation For The State University Of New York KVOPO4 cathode for sodium ion batteries

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2135111A (en) * 1936-04-27 1938-11-01 Harry J Prebluda Vanadyl lactate and process of making it
US4464357A (en) * 1983-05-26 1984-08-07 T&R Chemicals, Inc. Treatment of epilepsy with bisulfite
US4462988A (en) * 1983-05-26 1984-07-31 T&R Chemicals, Inc. Treatment of arthritis with bisulfite
US4657764A (en) * 1983-05-26 1987-04-14 T & R Chemicals, Inc. Treatment of arthritis and arthritic conditions with sulfites and bisulfites
DE3419686A1 (de) * 1983-05-26 1984-11-29 T and R Chemicals, Inc., Clint, Tex. Verwendung einer zusammensetzung mit therapeutischer wirksamkeit
US4532131A (en) * 1984-05-08 1985-07-30 T And R Chemicals, Inc. Therapeutic compositions

Also Published As

Publication number Publication date
IL81166A0 (en) 1987-08-31
JPS63239227A (ja) 1988-10-05
AU8316587A (en) 1988-07-07
IL81166A (en) 1990-03-19
US5045316A (en) 1991-09-03
EP0274404A1 (en) 1988-07-13
ZA8841B (OSRAM) 1988-06-24

Similar Documents

Publication Publication Date Title
AU594851B2 (en) Pharmaceutical compositions and their use
JP4171526B2 (ja) ２，２′−ジチオ−ビス（エタンスルホネート）（ジメスナ）と組み合わせたシスプラチン組成物
KR20000049065A (ko) 바이러스성 감염증 및 암 치료용 벤즈이미다졸-2-카르바메이트
WO2001052868A9 (en) Combinations for treating neoplasms
AT393221B (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
EP1318804B1 (en) Iron compositions
JPH10500678A (ja) 新生物疾患および自己免疫疾患の治療または予防のためのマグネシウムベースの製品の使用
RU2541092C2 (ru) Бисглицинат-хелат железа для использования в пероральном лечении анемии у пациентов с целиакией
JPH11511136A (ja) 癌の成長を阻害するためのグリセオフルビンの使用
DE3402878A1 (de) Arzneimittel und die verwendung schwerloeslicher calcium- und/oder magnesiumverbindungen als arzneimittel
US20030216438A1 (en) Antimicrobial agent
IE54475B1 (en) Process for the production of an iron-selenuim trace element solution
GB2194885A (en) Pharmaceutical compositions containing vanadium
JP5792322B2 (ja) ビタミンｄおよびメトホルミン含有医薬組成物
AU2018348892B2 (en) Formulation containing A-decarbonized-5a androstane compound for increasing white blood cell and use thereof
US3367834A (en) Method and compositions for enhancing the utilization of iron by mammals
AU713337B2 (en) Remedies and preventives for stomatitis
JP2004536120A (ja) 細胞殺傷活性を有するカルシウム塩
JPH07215868A (ja) 細胞内グルタチオンを刺激する方法及び組成物
CN108030778A (zh) 二甲双胍在制备防治化疗药物引发组织损伤药物中的应用
CN107397810B (zh) 基于铁的氢氧化物－桃胶的磷结合剂、其制备方法及其应用
CZ290489B6 (cs) Léčivo pro léčení nebo profylaxi poąkození ozářením
Watson Effects of concurrent drug therapy and of feeding on plasma chloramphenicol levels after oral administration of chloramphenicol in dogs
Kuhlmann et al. Cytostatic drugs are without significant effect on digitoxin plasma level and renal excretion
AU629520B2 (en) A medicament